The impact of secondary hyperparathyroidism on the efficacy of antiresorptive therapy

Gyöngyvér Kincse, J. Varga, Péter Somogyi, Péter Szodoray, Péter Surányi, J. Gaál

Research output: Article

Abstract

Background: The aim of the present study was to assess whether the efficacy of bisphosphonate treatment is influenced by PTH levels measured in newly diagnosed osteoporotic patients and to identify the threshold value, beyond which PTH level negatively influences therapeutic efficacy. Methods. One hundred and thirty-eight osteoporotic patients were enrolled into the study. All subjects underwent laboratory screening, bone densitometry with DEXA, and x-ray imaging. The changes in bone density were evaluated after a mean follow-up period of 13.37 ± 1.29 months. Correlation analysis was performed on the clinical data of patients, the percentage changes of BMD values, and the PTH levels measured at the beginning of study, using SPSS software. Results: The mean age of the subjects was 64.82 ± 10.51 years, and the female-to-male ratio was 116/22. Baseline BMD value measured with AP DEXA scanning was 0.854 ± 0.108 g/cm2 in the L1-4 vertebrae and 0.768 ± 0.115 g/cm2 in the left femoral neck. By the end of the follow-up period, these values changed to 0.890 ± 0.111 g/cm2 and 0.773 ± 0.111 g/cm2, respectively. We found a statistically significant, negative correlation between PTH levels and the percentage changes of lumbar BMD values measured at the end of the follow-up (correlation coefficient R2 = 0.121, p <0.0001). The analysis of frequency histograms suggested that negative effects on bone might be expected above a PTH level of 60 pg/mL (7.3 pmol/L). Conclusion: Our findings imply that a baseline PTH level over 60 ng/mL can reduce the efficacy of bisphosphonate treatment.

Original languageEnglish
Article number244
JournalBMC Musculoskeletal Disorders
Volume13
DOIs
Publication statusPublished - 2012

Fingerprint

Secondary Hyperparathyroidism
Diphosphonates
Bone and Bones
Densitometry
Femur Neck
Bone Density
Spine
Therapeutics
Software
X-Rays

ASJC Scopus subject areas

  • Orthopedics and Sports Medicine
  • Rheumatology

Cite this

The impact of secondary hyperparathyroidism on the efficacy of antiresorptive therapy. / Kincse, Gyöngyvér; Varga, J.; Somogyi, Péter; Szodoray, Péter; Surányi, Péter; Gaál, J.

In: BMC Musculoskeletal Disorders, Vol. 13, 244, 2012.

Research output: Article

Kincse, Gyöngyvér ; Varga, J. ; Somogyi, Péter ; Szodoray, Péter ; Surányi, Péter ; Gaál, J. / The impact of secondary hyperparathyroidism on the efficacy of antiresorptive therapy. In: BMC Musculoskeletal Disorders. 2012 ; Vol. 13.
@article{270b21fad3064e20adf54b649aa92003,
title = "The impact of secondary hyperparathyroidism on the efficacy of antiresorptive therapy",
abstract = "Background: The aim of the present study was to assess whether the efficacy of bisphosphonate treatment is influenced by PTH levels measured in newly diagnosed osteoporotic patients and to identify the threshold value, beyond which PTH level negatively influences therapeutic efficacy. Methods. One hundred and thirty-eight osteoporotic patients were enrolled into the study. All subjects underwent laboratory screening, bone densitometry with DEXA, and x-ray imaging. The changes in bone density were evaluated after a mean follow-up period of 13.37 ± 1.29 months. Correlation analysis was performed on the clinical data of patients, the percentage changes of BMD values, and the PTH levels measured at the beginning of study, using SPSS software. Results: The mean age of the subjects was 64.82 ± 10.51 years, and the female-to-male ratio was 116/22. Baseline BMD value measured with AP DEXA scanning was 0.854 ± 0.108 g/cm2 in the L1-4 vertebrae and 0.768 ± 0.115 g/cm2 in the left femoral neck. By the end of the follow-up period, these values changed to 0.890 ± 0.111 g/cm2 and 0.773 ± 0.111 g/cm2, respectively. We found a statistically significant, negative correlation between PTH levels and the percentage changes of lumbar BMD values measured at the end of the follow-up (correlation coefficient R2 = 0.121, p <0.0001). The analysis of frequency histograms suggested that negative effects on bone might be expected above a PTH level of 60 pg/mL (7.3 pmol/L). Conclusion: Our findings imply that a baseline PTH level over 60 ng/mL can reduce the efficacy of bisphosphonate treatment.",
keywords = "Antiresorptive therapy, D vitamin status, Efficacy, PTH level",
author = "Gy{\"o}ngyv{\'e}r Kincse and J. Varga and P{\'e}ter Somogyi and P{\'e}ter Szodoray and P{\'e}ter Sur{\'a}nyi and J. Ga{\'a}l",
year = "2012",
doi = "10.1186/1471-2474-13-244",
language = "English",
volume = "13",
journal = "BMC Musculoskeletal Disorders",
issn = "1471-2474",
publisher = "BioMed Central",

}

TY - JOUR

T1 - The impact of secondary hyperparathyroidism on the efficacy of antiresorptive therapy

AU - Kincse, Gyöngyvér

AU - Varga, J.

AU - Somogyi, Péter

AU - Szodoray, Péter

AU - Surányi, Péter

AU - Gaál, J.

PY - 2012

Y1 - 2012

N2 - Background: The aim of the present study was to assess whether the efficacy of bisphosphonate treatment is influenced by PTH levels measured in newly diagnosed osteoporotic patients and to identify the threshold value, beyond which PTH level negatively influences therapeutic efficacy. Methods. One hundred and thirty-eight osteoporotic patients were enrolled into the study. All subjects underwent laboratory screening, bone densitometry with DEXA, and x-ray imaging. The changes in bone density were evaluated after a mean follow-up period of 13.37 ± 1.29 months. Correlation analysis was performed on the clinical data of patients, the percentage changes of BMD values, and the PTH levels measured at the beginning of study, using SPSS software. Results: The mean age of the subjects was 64.82 ± 10.51 years, and the female-to-male ratio was 116/22. Baseline BMD value measured with AP DEXA scanning was 0.854 ± 0.108 g/cm2 in the L1-4 vertebrae and 0.768 ± 0.115 g/cm2 in the left femoral neck. By the end of the follow-up period, these values changed to 0.890 ± 0.111 g/cm2 and 0.773 ± 0.111 g/cm2, respectively. We found a statistically significant, negative correlation between PTH levels and the percentage changes of lumbar BMD values measured at the end of the follow-up (correlation coefficient R2 = 0.121, p <0.0001). The analysis of frequency histograms suggested that negative effects on bone might be expected above a PTH level of 60 pg/mL (7.3 pmol/L). Conclusion: Our findings imply that a baseline PTH level over 60 ng/mL can reduce the efficacy of bisphosphonate treatment.

AB - Background: The aim of the present study was to assess whether the efficacy of bisphosphonate treatment is influenced by PTH levels measured in newly diagnosed osteoporotic patients and to identify the threshold value, beyond which PTH level negatively influences therapeutic efficacy. Methods. One hundred and thirty-eight osteoporotic patients were enrolled into the study. All subjects underwent laboratory screening, bone densitometry with DEXA, and x-ray imaging. The changes in bone density were evaluated after a mean follow-up period of 13.37 ± 1.29 months. Correlation analysis was performed on the clinical data of patients, the percentage changes of BMD values, and the PTH levels measured at the beginning of study, using SPSS software. Results: The mean age of the subjects was 64.82 ± 10.51 years, and the female-to-male ratio was 116/22. Baseline BMD value measured with AP DEXA scanning was 0.854 ± 0.108 g/cm2 in the L1-4 vertebrae and 0.768 ± 0.115 g/cm2 in the left femoral neck. By the end of the follow-up period, these values changed to 0.890 ± 0.111 g/cm2 and 0.773 ± 0.111 g/cm2, respectively. We found a statistically significant, negative correlation between PTH levels and the percentage changes of lumbar BMD values measured at the end of the follow-up (correlation coefficient R2 = 0.121, p <0.0001). The analysis of frequency histograms suggested that negative effects on bone might be expected above a PTH level of 60 pg/mL (7.3 pmol/L). Conclusion: Our findings imply that a baseline PTH level over 60 ng/mL can reduce the efficacy of bisphosphonate treatment.

KW - Antiresorptive therapy

KW - D vitamin status

KW - Efficacy

KW - PTH level

UR - http://www.scopus.com/inward/record.url?scp=84871479504&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84871479504&partnerID=8YFLogxK

U2 - 10.1186/1471-2474-13-244

DO - 10.1186/1471-2474-13-244

M3 - Article

C2 - 23227959

AN - SCOPUS:84871479504

VL - 13

JO - BMC Musculoskeletal Disorders

JF - BMC Musculoskeletal Disorders

SN - 1471-2474

M1 - 244

ER -